RE:RE:RE:New article published That's a different thing, this sounds like data where they've gone to actual human patients tumour material and screened it for Sortilin then matched those Sortilin levels to the patients disease and outcomes. It's a bit like a number of other science papers that have looked for Sortilin in various cancer patients. It might be an expansion on those microarray results if those commercial available microarrays come with details on patient outcomes. It's actual human tumour material they are talking about, I'm fairly sure of that. Think of those squares showing tissue material stained brown, it would be a large number of those where they could start doing stats to match intensity of brown staining to disease type and clinical outcomes.They did something similar in melanoma where they showed staining got stronger the later the stage of disease (p39 of the KOL event PDF). Presumably this is enough data to make it publishable.
This is an open access journal so the full paper will appear soon I expect.
Wino115 wrote:
Would like to read this too. I think they did show us the photos of the metastasizes on lung samples which backed up their statement (the pre and post administration on Th1902). But you're right, they never specifically identified lymph node metastices for mTNBC. From what I gather, that is the most prevalent location. Would be interesting to know if somethings happening in the lymph nodes that ramps up even more SORT1 in the tumor environments. If someone gets the paper, post it or the link. You could use the old THTXProxy email address too.
qwerty22 wrote:
Here, we report that high expression of the sortilin (SORT1) receptor correlates with the decreased survival in TNBC patients, and more importantly in those bearing lymph node metastases.
Sounds like that would be some completely new data we havent seen or heard about before. I can't find the full paper though.